Harvard-Led COSMOS Study Reveals Multivitamins' Impact on Biological Aging

A groundbreaking study published in Nature Medicine has found that daily multivitamin supplementation can modestly slow the pace of biological aging, with particularly pronounced effects among individuals whose biological age exceeds their chronological age. Conducted as part of the large-scale COcoa Supplement and Multivitamin Outcomes Study (COSMOS), this research analyzed DNA methylation patterns in blood samples from 958 healthy older adults, averaging 70 years old. The findings suggest that accessible interventions like over-the-counter multivitamins could play a role in promoting healthier aging, sparking interest across nutrition and gerontology fields at U.S. universities.

Led by investigators from Brigham and Women's Hospital and Harvard Medical School, the trial underscores the potential of everyday supplements to influence epigenetic markers of aging. While the effects are small—equivalent to about four months less biological aging over two years—they provide the first robust evidence from a randomized controlled trial linking multivitamins to slower epigenetic aging.

Understanding the COSMOS Trial: A Landmark in Nutrition Research

The COSMOS trial, sponsored by Mars Edge and Pfizer (now Haleon), enrolled over 21,000 U.S. adults aged 60 and older to evaluate the health impacts of cocoa extract and Centrum Silver multivitamins. This ancillary study focused on a subset of 958 participants randomized to one of four groups: multivitamin plus cocoa, multivitamin plus placebo, cocoa plus placebo, or double placebo. Blood samples collected at baseline, year one, and year two underwent DNA methylation analysis to track changes in five epigenetic clocks: PC Hannum, PC Horvath, PC PhenoAge, PC GrimAge, and DunedinPACE.

Epigenetic clocks measure biological age by assessing DNA methylation—chemical tags on DNA that regulate gene expression without altering the genetic code. These clocks, particularly second-generation ones like PC GrimAge and PC PhenoAge, predict mortality and age-related diseases more accurately than chronological age alone. The trial's rigorous double-blind design minimizes bias, making it a gold standard for supplement research conducted by Harvard-affiliated teams.

Key Findings: Multivitamins Target Second-Generation Epigenetic Clocks

Compared to placebo, daily Centrum Silver multivitamin-multimineral (MVM) supplementation significantly slowed the rate of increase in two mortality-predictive clocks. For PC GrimAge, the between-group difference was -0.113 years per year (95% CI: -0.205 to -0.020; P=0.017). For PC PhenoAge, it was -0.214 years per year (95% CI: -0.410 to -0.019; P=0.032). No significant effects were seen on first-generation clocks (PC Hannum, PC Horvath) or DunedinPACE, and cocoa extract showed no impact.

• MVM reduced PC GrimAge acceleration by about 1 month per year of use.
• Over two years, this equates to roughly 2 months slower aging on average.
• Effects were consistent across sexes and baseline health status.

Senior author Howard D. Sesso, ScD, MPH, from Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, noted, "It was exciting to see the benefits of a multivitamin linked with markers of biological aging."

Stronger Anti-Aging Effects in Biologically Older Individuals

The most compelling result emerged in subgroup analysis: MVM's benefits were amplified in participants with accelerated biological aging at baseline—those whose epigenetic age exceeded chronological age. For PC GrimAge, the effect was -0.236 years/year (95% CI: -0.380 to -0.091) in this group versus -0.013 years/year (95% CI: -0.130 to 0.104) in those with normal or decelerated aging (P for interaction=0.018).

This suggests multivitamins may address nutrient gaps more critically in those experiencing faster cellular wear-and-tear, potentially due to oxidative stress or inflammation. Co-author Yanbin Dong, MD, PhD, from Augusta University, highlighted plans for follow-up to assess persistence post-trial.Mass General Brigham Press Release

Such precision could guide personalized nutrition strategies, a growing focus in U.S. academic research programs.

Research Methods: Rigorous Design from Harvard Powerhouse

COSMOS-Mind, the ancillary study, leveraged linear mixed-effects models adjusted for age, sex, baseline clock values, recruitment source, and other arms. DNA methylation was profiled using array-based methods, ensuring high reproducibility. The multivitamin contained standard doses of 20+ vitamins/minerals, mirroring Centrum Silver Women 50+ and Men 50+.

This table summarizes core results, highlighting statistical significance in mortality-linked clocks.

Harvard and Brigham and Women's: Hubs for Aging and Nutrition Science

The study exemplifies collaborative research at top U.S. institutions. Brigham and Women's Hospital, a Harvard teaching affiliate, hosts the Division of Preventive Medicine, where lead authors like Sesso and JoAnn E. Manson (also Harvard Chan) drive large trials. Augusta University's Georgia Prevention Institute contributed expertise in epigenetic analysis via Haidong Zhu and Yanbin Dong.

Harvard T.H. Chan School's epidemiology department provides rigorous training, producing leaders in public health nutrition. Such work attracts funding from NIH, positioning these universities as leaders in gerontology.Explore research jobs in aging science at leading U.S. universities.

Limitations and Expert Perspectives

While promising, effects are modest, and clocks measure correlation, not causation, with clinical outcomes. Steve Horvath, clock developer at Altos Labs, called it "very interesting and rigorous," but noted small effects and need for replication.

• Small sample for epigenetics (958 vs. 21k total COSMOS).
• No direct mortality/healthspan data yet.
• Potential confounders like diet adherence.

Sesso emphasized, "The more we can learn about its potential health benefits, the better." Harvard Gazette Coverage

Implications for Public Health and University Research

If replicated, findings could shift guidelines for older adults, especially those biologically older, addressing subclinical deficiencies. U.S. universities like Harvard are expanding nutrition-aging programs, integrating epigenetics into curricula.Professor jobs in nutrition emphasize such translational research.

Broader COSMOS results show MVM benefits cognition and CVD, potentially mediated by epigenetics.

Future Directions: Ongoing COSMOS Analyses and Beyond

Teams plan post-trial follow-up and links to cognition, cancer, cataracts. Emerging fields like precision nutrition at career advice for researchers will advance this. Universities seek faculty for gerontology.Faculty positions abound.

Career Opportunities in Nutrition and Aging Research

U.S. universities drive demand for experts in epigenetic aging and nutrition. Harvard, Tufts' Human Nutrition Research Center, and others post openings in faculty, postdocs, research assistants. Skills in RCTs, biomarkers key.Research jobs, postdoc roles, and lecturer positions offer paths to impact aging science. Explore professor salaries and rate professors in nutrition.

Photo by Clay Banks on Unsplash

• PhD in Epidemiology/Nutrition: $100k+ starting.
• Postdocs: NIH-funded aging studies.
• Industry ties: Pfizer collaborations.

Conclusion: A Step Toward Healthier Longevity

Harvard's COSMOS findings position daily multivitamins as a simple tool against biological aging, especially for at-risk groups. As research evolves, U.S. higher ed leads innovation. Interested in this field? Check higher ed jobs, university jobs, career advice, and rate my professor for insights. Stay tuned for clinical translations.